Bone remodeling: A review of the bone microenvironment perspective for fragility fracture (osteoporosis) of the hip

Seminars in Cell and Developmental Biology

Volumn 19, Issue 5, 2008, Pages 467-472

  Fazzalari, Nicola L ^a,b  

^a HANSON INSTITUTE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Bone remodeling; Formation surface; Fragility fracture; Osteoporosis; Resorption surface

Indexed keywords

BONE MORPHOGENETIC PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; OSTEOCLAST DIFFERENTIATION FACTOR; PROSTAGLANDIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; WNT PROTEIN;

BIOSYNTHESIS; BONE DENSITY; BONE MINERAL; BONE MINERALIZATION; BONE REMODELING; BONE STRUCTURE; BONE TURNOVER; CATABOLISM; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW;

EID: 53849112946     PISSN: 10849521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcdb.2008.08.003     Document Type: Review

References (71)

1. Consensus Development Conference. Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 94 6 (1993) 646-650
2. Kanis J.A., Melton L.J., Christiansen C., Johnston C.C., and Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 9 8 (1994) 1137-1141
3. Melton L.J. How many women have osteoporosis now?. J Bone Miner Res 10 2 (1995) 175-177
4. Ross P.D. Osteoporosis. Frequency, consequences, and risk factors. Arch Intern Med 156 13 (1996) 1399-1411
5. Boonen S., and Singer A.J. Osteoporosis management: impact of fracture type on cost and quality of life in patients at risk for fracture I. Curr Med Res Opin 24 6 (2008) 1781-1788
6. Sambrook P.N., Seeman E., Phillips S.R., and Ebeling P.R. Preventing osteoporosis: outcomes of the Australian Fracture Prevention Summit. Med J Aust 176 (2002) 1-16
7. Pocock N.A., Culton N.L., and Harris N.D. The potential effect on hip fracture incidence of mass screening for osteoporosis. Med J Aust 170 10 (1999) 486-488
8. Cole Z.A., Dennison E.M., and Cooper C. Osteoporosis epidemiology update. Curr Rheumatol Rep 10 2 (2008) 92-96
9. Hui S.L., Slemenda C.W., and Johnston C.C. Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 81 6 (1988) 1804-1809
10. Kanis J.A., Black D., Cooper C., Dargent P., Dawson-Hughes B., De Laet C., et al. A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int 13 7 (2002) 527-536
11. Shipman A.J., Guy G.W., Smith I., Ostlere S., Greer W., and Smith R. Vertebral bone mineral density, content and area in 8789 normal women aged 33-73 years who have never had hormone replacement therapy. Osteoporos Int 9 5 (1999) 420-426
12. Heaney R.P. Is the paradigm shifting?. Bone 33 4 (2003) 457-465
13. Parfitt A.M. What is the normal rate of bone remodeling?. Bone 35 1 (2004) 1-3
14. Riggs B.L., and Melton L.J. Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res 17 1 (2002) 11-14
15. Hernandez C.J. How can bone turnover modify bone strength independent of bone mass?. Bone 42 6 (2008) 1014-1020
16. Eriksen E.F., Melsen F., and Mosekilde L. Reconstruction of the resorptive site in iliac trabecular bone: a kinetic model for bone resorption in 20 normal individuals. Metab Bone Dis Relat Res 5 5 (1984) 235-242
17. Maes C., Carmeliet P., Moermans K., Stockmans I., Smets N., Collen D., et al. Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Mech Dev 111 1-2 (2002) 61-73
18. Zelzer E., McLean W., Ng Y.S., Fukai N., Reginato A.M., Lovejoy S., et al. Skeletal defects in VEGF(120/120) mice reveal multiple roles for VEGF in skeletogenesis. Development 129 8 (2002) 1893-1904
19. Knothe Tate M.L., Adamsona J.R., Tamia A.E., and Bauer T.W. The osteocyte. Int J Biochem Cell Biol 36 1 (2004) 1-8
20. Jilka R.L., Weinstein R.S., Parfitt A.M., and Manolagas S.C. Quantifying osteoblast and osteocyte apoptosis: challenges and rewards. J Bone Miner Res 22 10 (2007) 1492-1501
21. Aguirre J.I., Plotkin L.I., Gortazar A.R., Millan M.M., O'Brien C.A., Manolagas S.C., et al. A novel ligand-independent function of the estrogen receptor is essential for osteocyte and osteoblast mechanotransduction. J Biol Chem 282 35 (2007) 25501-25508
22. Huber C., Collishaw S., Mosley J.R., Reeve J., and Noble B.S. Selective estrogen receptor modulator inhibits osteocyte apoptosis during abrupt estrogen withdrawal: implications for bone quality maintenance. Calcif Tissue Int 81 2 (2007) 139-144
23. Tatsumi S., Ishii K., Amizuka N., Li M., Kobayashi T., Kohno K., et al. Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab 5 6 (2007) 464-475
24. Dempster D.W., Arlot M.A., and Meunier P.J. Mean wall thickness and formation periods of trabecular bone packets in corticosteroid-induced osteoporosis. Calcif Tissue Int 35 4-5 (1983) 410-417
25. Eriksen E.F. Normal and pathological remodeling of human trabecular bone: three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease. Endocr Rev 7 4 (1986) 379-408
26. Fazzalari N.L., and Parkinson I.H. Fractal properties of cancellous bone of the iliac crest in vertebral crush fracture. Bone 23 1 (1998) 53-57
27. Tsangari H., Findlay D.M., Zannettino A.C.W., Pan B., Kuliwaba J.S., and Fazzalari N.L. Evidence for reduced bone formation relative to bone resorption in female femoral fragility fracture patients. Bone 39 6 (2006) 1226-1235
28. Tsangari H., Findlay D.M., and Fazzalari N.L. Structural and remodeling indices in the cancellous bone of the proximal femur across adulthood. Bone 40 1 (2007) 211-217
29. Kanis J.A., Johnell O., Oden A., Jonsson B., De Laet C., and Dawson A. Prediction of fracture from low bone mineral density measurements overestimates risk. Bone 26 4 (2000) 387-391
30. Wicks M., Garrett R., Vernon-Roberts B., and Fazzalari N.L. Absence of metabolic bone disease in the proximal femur in patients with fracture of the femoral neck. J Bone Joint Surg 64-B 3 (1982) 319-322
31. Fazzalari N.L., Darracott J., and Vernon-Roberts B. Histomorphometric changes in the trabecular structure of a selected stress region in the femur in patients with osteoarthritis and fracture of the femoral neck. Bone 6 3 (1985) 125-133
32. Frost H.M. Skeletal structural adaptations to mechanical usage (SATMU). 2. Redefining Wolff's law: the remodeling problem. Anat Rec 226 4 (1990) 414-422
33. Kobayashi S., Takahashi H., Ito A., Saito N., Nawata M., Horiuchi H., et al. Trabecular minimodeling in human iliac bone. Bone 32 2 (2003) 163-169
34. Ahlborg H.G., Johnell O., Turner C.H., Rannevik G., and Karlsson M.K. Bone loss and bone size after menopause. N Engl J Med 349 4 (2003) 327-334
35. Nalla R.K., Kruzic J.J., Kinney J.H., and Ritchie R.O. Effect of aging on the toughness of human cortical bone: evaluation by R-curves. Bone 35 6 (2004) 1240-1246
36. Bell K.L., Loveridge N., Power J., Garrahan N., Meggitt B.F., and Reeve J. Regional differences in cortical porosity in the fractured femoral neck. Bone 24 1 (1999) 57-64
37. Bell K.L., Loveridge N., Power J., Rushton N., and Reeve J. Intracapsular hip fracture: increased cortical remodeling in the thinned and porous anterior region of the femoral neck. Osteoporos Int 10 3 (1999) 248-257
38. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95 7 (1998) 3597-3602
39. Yasuda H., Shima N., Nakagawa N., Mochizuki S.I., Yano K., Fujise N., et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139 3 (1998) 1329-1337
40. Fazzalari N.L., Kuliwaba J.S., Atkins G.J., Forwood M.R., and Findlay D. The ratio of mRNA levels of receptor activator of nuclear factor kappa-B ligand (RANKL) to osteoprotegerin (OPG) correlates with bone remodeling indices in control human cancellous bone but not in osteoarthritis. J Bone Miner Res 16 6 (2001) 1015-1027
41. Haynes D.R., Crotti T.N., Potter A.E., Loric M., Atkins G.J., Howie D.W., et al. The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis. J Bone Joint Surg 83-B 6 (2001) 902-911
42. Crotti T.N., Ahern M.J., Lange K., Weedon H., Coleman M., Roberts-Thomson P.J., et al. Variability of RANKL and OPG staining in synovial tissue from patients with active rheumatoid arthritis: quantification using colour video image analysis. J Rheumatol 30 11 (2004) 2319-2324
43. Hofbauer L.C., Khosla S., Dunstan C.R., Lacey D.L., Spelsberg T.C., and Riggs B.L. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 140 9 (1999) 4367-4370
44. Yao Z., Lafage-Proust M.H., Plouët J., Bloomfield S., Alexandre C., and Vico L. Increase of both angiogenesis and bone mass in response to exercise depends on VEGF. J Bone Miner Res 19 9 (2004) 1471-1480
45. Street J., Bao M., deGuzman L., Bunting S., Peale Jr. F.V., Ferrara N., et al. Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci USA 99 15 (2002) 9656-9661
46. Furumatsu T., Shen Z.N., Kawai A., Nishida K., Manabe H., Oohashi T., et al. Endothelial growth factor principally acts as the main angiogenic factor in the early stage of human osteoblastogenesis. J Biochem 133 5 (2003) 633-639
47. Kitten A.M., and Andrews C.J. Endothelin-1 expression in long-term cultures of fetal rat calvarial osteoblasts: regulation by BMP-7. J Cell Physiol 187 2 (2001) 218-225
48. Veillette C.J., and von Schroeder H.P. Endothelin-1 down-regulates the expression of vascular endothelial growth factor-A associated with osteoprogenitor proliferation and differentiation. Bone 34 2 (2004) 288-296
49. McCarty M.F. Optimizing endothelial nitric oxide activity may slow endothelial aging. Med Hypotheses 63 4 (2004) 719-723
50. Baum O., Da Silva-Azevedo L., Willerding G., Wöckel A., Planitzer G., Gossrau R., et al. Endothelial NOS is main mediator for shear stress-dependent angiogenesis in skeletal muscle after prazosin administration. Am J Physiol Heart Circ Physiol 287 5 (2004) H2300-H2308
51. Lyons D., Roy S., Patel M., Benjamin N., and Swift C.G. Impaired nitric oxide-mediated vasodilatation and total body nitric oxide production in healthy old age. Clin Sci (Lond) 93 6 (1997) 519-525
52. Abe T., Hikiji H., Shin W.S., Koshikiya N., Shima S., Nakata J., et al. Targeting of iNOS with antisense DNA plasmid reduces cytokine-induced inhibition of osteoblastic activity. Am J Physiol Endocrinol Metab 285 3 (2003) E614-E621
53. Diniz P., Soejima K., and Ito G. Nitric oxide mediates the effects of pulsed electromagnetic field stimulation on the osteoblast proliferation and differentiation. Nitric Oxide 7 1 (2002) 18-23
54. Bakker A., Klein-Nulend J., and Burger E. Shear stress inhibits while disuse promotes osteocyte apoptosis. Biochem Biophys Res Commun 320 4 (2004) 1163-1168
55. Riley E.H., Lane J.M., Urist M.R., Lyons K.M., and Lieberman J.R. Bone morphogenetic protein-2: biology and applications. Clin Orthop Relat Res 324 (1996) 39-46
56. McGee M.A., Findlay D.M., Howie D.W., Carbone A., Ward P., Stamenkov R., et al. The use of OP-1 in femoral impaction grafting in a sheep model. J Orthop Res 22 5 (2004) 1008-1015
57. Balemans W., Piters E., Cleiren E., Ai M., Van Wesenbeeck L., Warman M.L., et al. The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations. Calcif Tissue Int June (2008) [Epub ahead of print]
58. Poole K.E., van Bezooijen R.L., Loveridge N., Hamersma H., Papapoulos S.E., Löwik C.W., et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 19 13 (2005) 1842-1844
59. Kusu N., Laurikkala J., Imanishi M., Usui H., Konishi M., Miyake A., et al. Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. J Biol Chem 278 26 (2003) 24113-24117
60. ten Dijke P., Krause C., de Gorter D.J.J., Löwik C.W.G.M., and van Bezooijen R.L. Morphogenetic protein and wnt signaling osteocyte-derived sclerostin inhibits bone formation: its role in bone. J Bone Joint Surg Am 90 Suppl. 1 (2008) 31-35
61. Baron R., and Rawadi G. Wnt signaling and the regulation of bone mass. Curr Osteoporos Rep 5 2 (2007) 73-80
62. Westendorf J.J., Kahler R.A., and Schroeder T.M. Wnt signaling in osteoblasts and bone diseases. Gene 341 (2004) 19-39
63. Piters E., Boudin E., and van Hul W. Wnt signaling: a win for bone. Arch Biochem Biophys 473 2 (2008) 112-116
64. Tian E., Zhan F., Walker R., Rasmussen E., Ma Y., Barlogie B., et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349 26 (2003) 2483-2494
65. Mundy G.R. Osteoporosis and inflammation. Nutr Rev 65 12 Pt 2 (2007) S147-S151
66. Mountziaris P.M., and Mikos A.G. Modulation of the inflammatory response for enhanced bone tissue regeneration. Tissue Eng, Part B: Rev 14 2 (2008) 179-186
67. Gaffen S.L. Biology of recently discovered cytokines: interleukin-17-a unique inflammatory cytokine with roles in bone biology and arthritis. Arthritis Res Ther 6 6 (2004) 240-247
68. Goldring S.R. 2003 Inflammatory mediators as essential elements in bone remodelling. Calcif Tiss Int 73 2 (2003) 97-100
69. Pfeilschifter J., Köditz R., Pfohl M., and Schatz H. Changes in proinflammatory cytokine activity after menopause. Endocr Rev 23 1 (2002) 90-119
70. Robinson L.J., Borysenko C.W., and Blair H.C. Tumor necrosis factor family receptors regulating bone turnover: new observations in osteoblastic and osteoclastic cell lines. Ann NY Acad Sci 1116 (2007) 432-443
71. Tsangari H., Findlay D., Kuliwaba J.S., Atkins G.J., and Fazzalari N.L. Increased expression of IL-6 and RANKL mRNA in human trabecular bone from fragility fracture of the femoral neck. Bone 35 1 (2004) 334-342